Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

HUVEC cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADAMTS (1) Akt (3) Anaplastic lymphoma kinase (ALK) (1) Angiotensin Receptor (1) Antibiotic (1) AP-1 (1) Apelin Receptor (APJ) (1) Apoptosis (13) Autophagy (4) Bacterial (5) Bcl-2 Family (1) c-Kit (4) Calcium Channel (2) CCR (2) Cholinesterase (ChE) (1) Deubiquitinase (1) DNA/RNA Synthesis (1) Endogenous Metabolite (5) ERK (3) FAK (1) FGFR (4) Fluorescent Dye (1) HBV (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Methyltransferase (1) HSP (1) HSV (1) iGluR (1) Integrin (4) Keap1-Nrf2 (1) LPL Receptor (1) MDM-2/p53 (1) MetAP (2) Microtubule/Tubulin (2) Molecular Glues (1) mTOR (1) NF-κB (4) p38 MAPK (1) Parasite (1) PDGFR (4) PERK (1) Piezo Channel (1) PKC (3) PPAR (1) Progesterone Receptor (1) Raf (4) Reactive Oxygen Species (3) RET (3) Small Interfering RNA (siRNA) (1) Src (1) Tie (3) Topoisomerase (1) VEGFR (14) Xanthine Oxidase (2) YAP (1)
By Research Areas:	Cancer (38) Cardiovascular Disease (15) Endocrinology (2) Infection (9) Inflammation/Immunology (17) Metabolic Disease (3) Neurological Disease (4)

By Targets:

ADAMTS (1)

Akt (3)

Anaplastic lymphoma kinase (ALK) (1)

Angiotensin Receptor (1)

Antibiotic (1)

AP-1 (1)

Apelin Receptor (APJ) (1)

Apoptosis (13)

Autophagy (4)

Bacterial (5)

Bcl-2 Family (1)

c-Kit (4)

Calcium Channel (2)

CCR (2)

Cholinesterase (ChE) (1)

Deubiquitinase (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (5)

ERK (3)

FAK (1)

FGFR (4)

Fluorescent Dye (1)

HBV (1)

HIF/HIF Prolyl-Hydroxylase (3)

Histone Methyltransferase (1)

HSP (1)

HSV (1)

iGluR (1)

Integrin (4)

Keap1-Nrf2 (1)

LPL Receptor (1)

MDM-2/p53 (1)

MetAP (2)

Microtubule/Tubulin (2)

Molecular Glues (1)

mTOR (1)

NF-κB (4)

p38 MAPK (1)

Parasite (1)

PDGFR (4)

PERK (1)

Piezo Channel (1)

PKC (3)

PPAR (1)

Progesterone Receptor (1)

Raf (4)

Reactive Oxygen Species (3)

RET (3)

Small Interfering RNA (siRNA) (1)

Src (1)

Tie (3)

Topoisomerase (1)

VEGFR (14)

Xanthine Oxidase (2)

YAP (1)

By Research Areas:

Cancer (38)

Cardiovascular Disease (15)

Endocrinology (2)

Infection (9)

Inflammation/Immunology (17)

Metabolic Disease (3)

Neurological Disease (4)

Inhibitors & Agonists

Fluorescent Dye

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W009749

L-Cystathionine	Endogenous Metabolite Apoptosis	Cardiovascular Disease
L-Cystathionine is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine plays an important role in cardiovascular protection .

HY-161313

DYB-03	Histone Methyltransferase HIF/HIF Prolyl-Hydroxylase	Cancer
DYB-03 is an oral active HIF-1α/EZH2 inhibitor. DYB-03 inhibits migration, invasion, and angiogenesis of lung cancer cells and HUVECs in vitro and in vivo. DYB-03 induces apoptosis in 2-ME2 ^- and GSK126 ^-resistant of A549 and H460 cells .

HY-147891

Angiogenesis inhibitor 3	Apoptosis	Cancer
Angiogenesis inhibitor 3 (compound 8) is a potent angiogenesis inhibitor. Angiogenesis inhibitor 3 inhibits the proliferation of HUVEC and HCT-15 cells, with IC₅₀ values of 1.00 and 0.71 μM. Angiogenesis inhibitor 3 induces the apoptosis of HUVEC and HCT-15 cells. Angiogenesis inhibitor 3 shows anticancer activity, and suppresses the invasion of cancer cells. Angiogenesis inhibitor 3 inhibits the angiogenesis in zebrafish embryos .

HY-147890

Angiogenesis inhibitor 2	Apoptosis	Cancer
Angiogenesis inhibitor 2 (compound 72) is a potent angiogenesis inhibitor. Angiogenesis inhibitor 2 inhibits the proliferation of HUVEC and HCT-15 cells, with IC₅₀ values of 1.93 and 0.21 μM. Angiogenesis inhibitor 2 induces the apoptosis of HUVEC and HCT-15 cells. Angiogenesis inhibitor 2 shows anticancer activity, and suppresses the invasion of cancer cells. Angiogenesis inhibitor 2 inhibits the angiogenesis in zebrafish embryos .

HY-18318

Takeda-6D	Raf VEGFR PERK	Cancer
Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC₅₀ values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity .

HY-149921

Antiangiogenic agent 3	Others	Cancer
Antiangiogenic agent 3 (compound 3) is a potent antiangiogenic agent. Antiangiogenic agent 3 is an inhibitor of human umbilical vein endothelial cells (HUVEC). Antiangiogenic agent 3 inhibits HUVEC migration and chemotactic motilities. Antiangiogenic agent 3 also decreases the gene expression of Src, cdc42, and MAPK .

HY-P5877

ɛPKC(85–92),Myristoylated	PKC	Inflammation/Immunology
?PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC? peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-P5888

PKCε inhibitor peptide,myristoylated Myr‐PKCɛ-	PKC	Inflammation/Immunology
PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated PKC? peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-155174

Antiangiogenic agent 4

Akt Cancer

Antiangiogenic agent 4 (Compound 3b) inhibits Akt phosphorylation in HFF and HUVEC cells. Antiangiogenic agent 4 can be used for cancer research .

Antiangiogenic agent 4	Akt	Cancer
Antiangiogenic agent 4 (Compound 3b) inhibits Akt phosphorylation in HFF and HUVEC cells. Antiangiogenic agent 4 can be used for cancer research .

HY-103316

trans-Ned 19	Calcium Channel	Cardiovascular Disease
trans-Ned 19, a NAADP antagonist and TPC blocker, suppresses the calcium signal in human umbilical vein endothelial cells (HUVEC) and the rat aorta relaxation in response to low histamine concentrations .

HY-N8248

Eleutherin (+)-Eleutherin	Others Topoisomerase	Cardiovascular Disease
Eleutherin is a type of naphthoquinone derivative with the protective effect against the injury ofhuman umbilical vein endothelial cells (HUVECs), which can be isolated from the edible bulbs of Eleutherine americana (Hong-Cong) .

HY-N6737

Aureothricin	Bacterial Antibiotic	Infection
Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelial cells (HUVECs) to vitronectin .

HY-W588250

Surfactin C1	Integrin	Inflammation/Immunology
Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelial cells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .

HY-115436

LYG-202	Apoptosis	Cancer
LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .

HY-161330

Anti-MRSA agent 10	Bacterial	Infection
Anti-MRSA agent 10 (Compound 2d) is a Cephalosporin (HY-144229) derivative and exhibits antibacterial activity. Anti-MRSA agent 10 is slightly drug resistane and exhibits low cytotoxicity in cells HUVEC and HBZY-1 .

HY-W800162

VEGFR-2-IN-37	VEGFR	Cancer
VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .

HY-W009749C

L-Cystathionine dihydrochloride	Endogenous Metabolite Apoptosis	Cardiovascular Disease
L-Cystathionine (dihydrochloride) is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine (dihydrochloride) protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine (dihydrochloride) plays an important role in cardiovascular protection .

HY-156081

Nrf2 activator-9	Keap1-Nrf2 Apoptosis	Metabolic Disease
Nrf2 activator-9 (compound D-36) is an Nrf2 activator that inhibits oxidized low-density lipoprotein (oxLDL) and high glucose (HG)-induced apoptosis in HUVEC cells. Nrf2 activator-9 inhibits oxLDL and HG-induced vascular endothelial cell (VEC) injury and can effectively prevent and treat atherosclerosis .

HY-N4094

Morellic acid

Others Inflammation/Immunology

Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity .

Morellic acid	Others	Inflammation/Immunology
Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity .

HY-N2132

Flavokawain B 1 Publications Verification Flavokavain B	Apoptosis	Cancer
Flavokawain B (Flavokavain B) is a chalcone isolated from the root extracts of kava-kava plant and a potent apoptosis inducer for inhibiting the growth of various cancer cell lines. Flavokawain B (Flavokavain B) shows strong antiangiogenic activity. Flavokawain B (Flavokavain B) inhibits human brain endothelial cell (HUVEC) migration and tube formation with very low and non-toxic concentrations .

HY-125919

Vulpinic acid	Reactive Oxygen Species Bacterial Endogenous Metabolite	Infection Inflammation/Immunology
Vulpinic acid, a lichen metabolite, decreases H₂O₂-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC). Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research .

HY-101015

(2E)-OBAA
(2E)-OBAA is a potent phospholipase A2 (PLA2) inhibitor, with an IC₅₀ of 70 nM. (2E)-OBAA induces apoptosis of HUVEC cells. (2E)-OBAA blocks Melittin-induced Ca ²⁺ influx in Trypanosoma brucei, with an IC₅₀ of 0.4 μM .

HY-W013557

3-Hydroxyxanthone 3-Hydroxy-xanthen-9-one	Integrin	Inflammation/Immunology
3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one) is a xanthone compound, with . 3-Hydroxyxanthone inhibits NADPH-catalysed lipid peroxidation in human umbilical vein endothelial cells (HUVECs). 3-Hydroxyxanthone also inhibits TNF-alpha induced ICAM-1 expression .

HY-N2927

Costic acid β-Costic acid	Parasite	Infection
Costic acid (β-Costic acid) is a natural product, that can be isolated from Dittrichia viscosa. Costic acid exhibits potent in vivo acaricidal activity against the parasite. Costic acid is not toxic for human umbilical vein endothelial cells (HUVEC) at concentrations of up to 230 μM. Costic acid can be used for the research of varroosis in honey bee colonies .

HY-133924

18-Deoxyherboxidiene RQN-18690A	Others	Cardiovascular Disease Cancer
18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research .

HY-147949

SKLB0565	Microtubule/Tubulin Apoptosis	Cancer
SKLB0565 is a potent tubulin inhibitor. SKLB0565 shows significant anti-proliferative activity against CRC (colorectal carcinoma) cell lines, with IC₅₀ values ranging from 0.012 μM to 0.081 μM. SKLB0565 causes G2/M phase arrest and mitochondria-mediated intrinsic apoptosis. SKLB0565 inhibits cell migration and disrupted the tube formation of HUVECs .

HY-13645

Henatinib	VEGFR c-Kit PDGFR	Cancer
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC₅₀ values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .

HY-P99333

Volociximab M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-108933

JK-P3	VEGFR FGFR	Cancer
JK-P3 is a potent and pan VEGFR2 inhibitor, with IC₅₀s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity .

HY-151996

Tubulin inhibitor 31	Microtubule/Tubulin	Cardiovascular Disease
Tubulin inhibitor 31 is a potent tubulin inhibitor with an IC₅₀ value of 4 µM. Tubulin inhibitor 31 shows anti-proliferative activity. Tubulin inhibitor 31 inhibits the HUVEC migration .

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Infection Inflammation/Immunology Cancer
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .

HY-126010

Dooku1 5 Publications Verification	Piezo Channel	Others
Dooku1 is a reversibly Yoda1 antagonist with IC₅₀ value of 1.3 μM and 1.5 μM for 2 μM Yoda1-induced Ca ²⁺ entry HEK 293 cells and HUVECs, respectively. Dooku1 can disrupt Yoda1-induced Piezo1 channel activity and inhibit Yoda1-induced relaxation of aorta. Dooku1 can be used for vascular physiology and disease research .

HY-115831

SAR247799 S1P1 agonist 3	LPL Receptor	Cardiovascular Disease
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC₅₀s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome .

HY-125783

1-Palmitoyl-sn-glycero-3-phosphocholine	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
1-Palmitoyl-sn-glycero-3-phosphocholine is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .

HY-P4002

Adamtsostatin 18	ADAMTS	Cancer
Adamtsostatin 18 is an anti-angiogenic peptide derived from proteins containing type I thrombospondin motifs. Adamtsostatin 18 inhibits cell migration and proliferation .

HY-152100

CUR5g	Autophagy	Cancer
CUR5g is a potent autophagy inhibitor. CUR5g selectively inhibits autophagosome degradation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocks the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g improves the anticancer effect of Cisplatin (HY-17394) against A549 cells both in vitro and in vivo .

HY-120200

YF-452	VEGFR	Cardiovascular Disease Cancer
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .

HY-P3418

CKLF1-C27	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .

HY-P3418A

CKLF1-C27 TFA	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .

HY-P2196A

ELA-32(human) TFA	Apelin Receptor (APJ)	Cancer
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC₅₀=0.27 nM; K_d=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.

HY-155721

22-(4′-py)-JA 22-(4′-Pyridinecarbonyl) jorunnamycin A	Akt mTOR	Cancer
22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .

HY-B0648

Medroxyprogesterone 5+ Cited Publications 17α-Hydroxy-6α-methylprogesterone; U8840	Progesterone Receptor	Endocrinology Cancer
Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469) .

HY-138284

Avenanthramide-C methyl ester	NF-κB	Inflammation/Immunology
Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity .

HY-158006

SDX-7539	MetAP	Cancer
SDX-7539 is a selective inhibitor for Methionine aminopeptidase type 2 (MetAP2). SDX-7539 inhibits proliferarion of HUVECs with an IC₅₀ of 120 μM. SDX-7539 exhibits antitumor activity in NSCLC xenograft athymic nude mice .

HY-N0515

Ophiopogonin D	PPAR NF-κB Calcium Channel	Cardiovascular Disease Inflammation/Immunology
Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C₂₉ steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca ²⁺ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-122627

CLZ-8	Bcl-2 Family Apoptosis	Cancer
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a K_i of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells .

HY-112291

SB 220025	p38 MAPK Src PKC	Inflammation/Immunology
SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC₅₀ = 60 nM). SB 220025 also inhibits p56 ^Lck and PKC with IC₅₀ values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .

HY-17505

Candesartan Cilexetil 2 Publications Verification TCV-116	Angiotensin Receptor Apoptosis	Cardiovascular Disease Endocrinology
Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .

HY-14571

E7820 4 Publications Verification ER68203-00	Molecular Glues Integrin	Cancer
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC₅₀ of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity .

HY-112467

Tivozanib hydrate AV-951 hydrate; KRN951 hydrate	VEGFR	Cancer
Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy .

Cat. No.	Product Name	Target	Research Area